Claims
- 1. A pharmaceutical formulation in unit dosage form adapted for oral administration to achieve an antisecretory effect, comprising per dosage unit an antisecretorially-effective amount of N-methyl-N'-2-(2-dimethylaminomethyl-4-thiazolylmethylthio)ethyl 2-nitro-1,1-ethenediamine or a pharmaceutically acceptable acid addition salt thereof plus one or more pharmaceutical excipients.
- 2. A pharmaceutical formulation according to claim 1 containing from 50-80 mg. of active drug per dosage unit.
- 3. A method for inhibiting gastric acid secretion in mammals which comprises administering to a mammal, whose gastric acid secretion is excessive and who is in need of treatment, an antisecretorially-effective amount of N-methyl-N'-2-(2-dimethylaminomethyl-4-thiazolylmethylthio)ethyl 2-nitro-1,1-ethenediamine or a pharmaceutically acceptable acid addition salt thereof.
- 4. A method according to claim 3 in which from 140-350 mg. of drug per day are administered orally to humans.
- 5. A method according to claim 3 in which the oral daily dose is from 2-5 mg./kg. of mammalian body weight.
- 6. A method according to claim 3 in which the antisecretory drug is administered orally.
- 7. A method according to claim 3 in which the antisecretory drug is administered parenterally.
CROSS-REFERENCE
This application is a continuation-in-part of my copending application Ser. No. 193,192, filed Oct. 2, 1980 now U.S. Pat. No. 4,375,547, issued 3/1/83.
US Referenced Citations (8)
Foreign Referenced Citations (2)
Number |
Date |
Country |
1421792 |
Jan 1976 |
GBX |
1574214 |
Sep 1980 |
GBX |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
193192 |
Oct 1980 |
|